Introducing the Anti-RNase L In Vivo Antibody - Low Endotoxin from Assay Genie, a highly specific monoclonal antibody designed for in vivo applications. This antibody targets the RNase L protein, a key player in the antiviral and apoptotic responses, making it essential for research in virology, oncology, and innate immunity. With optimal isotypes ensuring high purity and low endotoxin levels (<1.0 EU/mg), it is perfect for a variety of applications including ELISA, immunoprecipitation, Western blot, and other assays.
Available in various sizes, this antibody is formulated in a phosphate-buffered saline solution to ensure stability and efficacy, enhancing the reliability of your research results.
Elevate your research with this dependable and versatile antibody.
RNase L (Ribonuclease L) is an enzyme that is involved in the cellular antiviral defense mechanism. This protein mediates the degradation of viral RNA and has roles in controlling cell proliferation and inducing apoptosis, making it a crucial component in the host's defense against viral infections and cancer development.
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:
< 1.0 EU/mg as determined by the LAL method
Purity:
≥95% monomer by analytical SEC â‹… >95% by SDS Page
Product Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Applications:
ELISA, IHC FFPE, In Vivo, WB
Reactivity:
Human/Hamster/Primate
Host Species:
Mouse
Specificity:
Clone 2E9 recognizes an epitope on human/hamster/primate RNaseL.
Antigen Distribution:
RNase L is highly expressed in the spleen and thymus, followed by prostate, testis, uterus, small intestine, colon, and peripheral blood leukocytes.
Immunogen:
Purified, full-length, recombinant, human RNaseL produced in insect cells.
Concentration:
≥ 5.0 mg/ml
Endotoxin Level:
< 1.0 EU/mg as determined by the LAL method
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Purity:
≥95% monomer by analytical SEC â‹… >95% by SDS Page
Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
RNase L antibody, clone 2E9, recognizes the interferon (IFN)-inducible 2-5A-dependent ribonuclease L (RNase L), an endoribonuclease involved in antiviral signaling. It is widely expressed as a latent monomer in most mammalian tissues1. 2’,5’-oligoadenylate synthetase (OAS) is expressed following viral infection and exposure to IFN2. OAS proteins are activated by dsRNA, resulting in the production of 2’,5’-linked oligoadenylates (2-5A), which bind to latent RNase L, inducing dimerization and activation2. RNase L inhibits viral replication by cleaving viral and ribosomal RNA3,4 and inducing apoptosis in virus-infected cells5,6. RNase L is suggested to have antitumor effects, possibly through its pro-apoptotic activity7, and mutations in the RNASEL gene are associated with prostate cancer risk and progression8,9.
